Aethlon Medical (AEMD) investor relations material

Company overview and business model

• Focuses on developing the Hemopurifier, a clinical-stage immunotherapeutic device for cancer, viral infections, and organ transplantation.

• Hemopurifier uses proprietary lectin-based technology to remove harmful exosomes and viruses from plasma.

• FDA has designated Hemopurifier as a Breakthrough Device for advanced/metastatic cancer and life-threatening viruses.

• Ongoing clinical trials in Australia for oncology; prior trials in India and the US for viral indications.

• Holds a portfolio of patents and trademarks related to extracorporeal removal of microvesicular particles and viral infections.

Financial performance and metrics

• No revenue generated in fiscal years ended March 31, 2026 and 2025; prior revenue from government contracts.

• Research and development expenses were approximately $1.91 million in FY 2026 and $2.21 million in FY 2025.

• Cash and cash equivalents of approximately $5 million as of March 31, 2026.

• Significant operating losses and substantial doubt about ability to continue as a going concern for 12 months post-financial statement date.

Use of proceeds and capital allocation

• Estimated net proceeds of $10.8 million from the offering, assuming full subscription.

• Proceeds intended for general corporate purposes, including R&D, clinical trials, capital expenditures, and working capital.

• May use a portion for in-licensing, acquisitions, or investments in complementary businesses or technologies.

• Management has broad discretion over allocation of proceeds.